Why Indian drugmakers are losing pricing power in the US | Today’s news
Strong buyers, the end of limits on generic Revlimid and rapidly weakening launches are pushing Indian drugmakers’ US deals. Complex products offer a way to protect pricing power, but developing them requires higher R&D expenditures and years of investment before they can replace lost revenue.